Petrovic Nebojsa S, Grujicic Danica, Artiko Vera M, Sobic-Saranovic Dragana P, Gajic Milan M, Jaksic Emilija, Grajic Mirko M, Antonovic Olga J, Petrovic Milorad N, Obradovic Vladimir B
Centre for Nuclear Medicine, Belgrade University School of Medicine, Belgrade, Republic of Serbia.
Nucl Med Commun. 2010 Nov;31(11):962-73. doi: 10.1097/MNM.0b013e32833ea6cc.
(i) To examine blood perfusion and metabolic activity of various brain tumours using radionuclide cerebral angiography (RCA) and single-photon emission tomography (SPET) after a single dose of Tc-methoxyisobutylisonitrile (MIBI). (ii) To examine if the inclusion of RCA can improve insight into the relative contribution of tumour perfusion to the uptake of MIBI shown by SPET, and to improve evaluation of tumour biology. (iii) To determine the value and the roles of MIBI in the management of brain tumour patients.
Fifty adult patients (38 male, 12 female) with a total of 56 intracranial space-occupying lesions have been included prospectively, 37 of which were newly diagnosed and the remaining with signs of recurrence/rest of earlier resected and irradiated brain tumours. The control group consisted of nine volunteers with no evidence of organic cerebral disease. Scintigraphic examination consisted of a dynamic first-pass study lasting 60 s (3 s/frame) and two SPET studies (60 projections each, 25 s/projection), starting 15 min and 2 h after intravenous injection of MIBI. Regions of interest of the tumour and normal brain tissue were drawn on RCA and both early and delayed SPET slices. The following tumour/brain activity ratios have been calculated: (i) tumour perfusion index (P); (ii) early uptake index (E); (iii) delayed uptake index (D); and(iv) retention index (R). Analogous indices have been calculated from the same examinations performed in controls, reflecting maximal physiologic regional variations of perfusion and uptake in brain tissue.
Mean P of various brain tumours (low-grade gliomas 0.98, anaplastic gliomas 1.14, glioblastoma multiforme 1.20, metastases 1.09, lymphomas 1.08) differ little from each other and do not exceed maximal physiologic regional variations of cerebral perfusion (1.33), with the exception of meningioma (1.87, F=2.83, P=0.015). The receiver operating characteristics curve analysis of P showed that for the cut-off value of 1.45 the sensitivity for distinguishing meningioma from other tumours is 75%, specificity 87%, positive predictive value 33% and negative predictive value 97%. Mean E of malignant brain tumours (8.3, n=31, 23 primary, eight secondary), except anaplastic gliomas (3.5, n=5), differed significantly (P=0.02) from those of benign gliomas (3, n=9) but not from that of meningioma (11.9, n=4). The cut-off value for distinguishing malignant from benign lesions on the basis of E set at 4.8 resulted in sensitivity 67%, specificity 75%, accuracy 70%, positive predictive value 80% and negative predictive value 60%. D and R showed tendency of wash-out of MIBI from meningiomas, but otherwise did not improve the results substantially.
Integrated results of RCA and SPET with Tc-MIBI indicate that blood perfusion, blood-tumour barrier permeability and metabolic activity of the tumour are all very important for the resultant uptake shown by SPET. If the perfusion index is less than 1.45, then meningioma can be ruled out. Early SPET is recommendable for distinguishing glioblastoma from low-grade gliomas, as a complement to standard magnetic resonance imaging and/or computed tomography.
(i)在单次注射锝-甲氧基异丁基异腈(MIBI)后,使用放射性核素脑血管造影(RCA)和单光子发射断层扫描(SPET)检查各种脑肿瘤的血液灌注和代谢活性。(ii)检查纳入RCA是否能增进对肿瘤灌注对SPET所示MIBI摄取的相对贡献的了解,并改善对肿瘤生物学的评估。(iii)确定MIBI在脑肿瘤患者管理中的价值和作用。
前瞻性纳入了50例成年患者(38例男性,12例女性),共有56个颅内占位性病变,其中37例为新诊断病例,其余为早期切除并接受放疗的脑肿瘤复发/残留迹象患者。对照组由9名无器质性脑病证据的志愿者组成。闪烁扫描检查包括持续60秒(3秒/帧)的动态首过研究和两次SPET研究(每次60个投影,25秒/投影),在静脉注射MIBI后15分钟和2小时开始。在RCA以及早期和延迟SPET切片上绘制肿瘤和正常脑组织的感兴趣区域。计算了以下肿瘤/脑活性比值:(i)肿瘤灌注指数(P);(ii)早期摄取指数(E);(iii)延迟摄取指数(D);以及(iv)滞留指数(R)。从对照组进行的相同检查中计算出类似指数,反映脑组织灌注和摄取的最大生理性区域差异。
各种脑肿瘤的平均P值(低级别胶质瘤0.98,间变性胶质瘤1.14,多形性胶质母细胞瘤1.20,转移瘤1.09,淋巴瘤1.08)彼此差异不大,且除脑膜瘤(1.87,F=2.83,P=0.015)外,均未超过脑灌注的最大生理性区域差异(1.33)。P的受试者操作特征曲线分析表明,对于截断值1.45,区分脑膜瘤与其他肿瘤的敏感性为75%,特异性为87%,阳性预测值为33%,阴性预测值为97%。恶性脑肿瘤(8.3,n=31,23例原发性,8例继发性)的平均E值,除间变性胶质瘤(3.5,n=5)外,与良性胶质瘤(3,n=9)有显著差异(P=0.02),但与脑膜瘤(11.9,n=4)无显著差异。基于E区分恶性与良性病变的截断值设定为4.8时,敏感性为67%,特异性为75%,准确性为70%,阳性预测值为80%,阴性预测值为60%。D和R显示MIBI从脑膜瘤中有洗脱趋势,但在其他方面并未显著改善结果。
RCA和SPET与锝- MIBI的综合结果表明,肿瘤的血液灌注、血肿瘤屏障通透性和代谢活性对SPET所示的最终摄取均非常重要。如果灌注指数小于1.45,则可排除脑膜瘤。早期SPET对于区分胶质母细胞瘤与低级别胶质瘤是可取的,可作为标准磁共振成像和/或计算机断层扫描的补充。